Last reviewed · How we verify

Ebixa — Competitive Intelligence Brief

Ebixa (Ebixa) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Ebixa (Ebixa) — Konkuk University Medical Center.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ebixa TARGET Ebixa Konkuk University Medical Center marketed Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase
Namenda Namenda Inova Health Care Services marketed Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ebixa — Competitive Intelligence Brief. https://druglandscape.com/ci/ebixa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: